Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gemcitabine-based chemotherapy as first-line maintenance for advanced pancreatic cancer
ChiCTR1800019969Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Rivoceranibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1800019969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019969.